Performance Enhancing Drugs Market Research Report – Global Forecast till 2027

Performance Enhancing Drugs Market Research Report: By Types (Ergogenic Aids, Nootropic), By Products (Pills, Injections, Patches), By End Users (Athletes, Body Builders, Students, Militaries), and Others- Global Forecast Till 2027

ID: MRFR/Pharma/3274-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


Performance enhancing drugs are chemical agents designed to provide an advantage in athletic performance. Muscle enlargement, increased blood’s oxygen carrying capacity are some of the effects induced by the consumption of the performance enhancing drugs. In 2015, according to Health Research Funding ~1,084,000 Americans were reported to use anabolic performance enhancing drugs. Along with such trends in the usage of the performance enhancing drugs, increasing acceptance is facilitating the market growth. Approximately 57% of the steroid users said that they would continue to use steroids even if it shortens there life. Moreover, increasing use of the anabolic steroids for the treatment of medical conditions such as anaemia, certain kinds of breast cancer besides others is expected to fuel the market growth during the forecasted period. However, the use of such drugs leads to various side effects. Some of the side effects observed in males are acne, diminished sperm production; in females,  masculinization, heart attack, etc. Moreover, in 2014 according to the Health Research Funding, the percentage of positive tests for anabolic drugs doping in world was about 50.6%. Such cases of doping made the governments to formulate strict guidelines for the usage and sales of performance enhancing drugs. This is expected to restrict the market growth during the forecasted period. 
The global market for performance enhancing drugs is expected to grow at an approximate CAGR of 4.8%. 


Intended Audience



  • Pharmaceutical Companies

  • Sports Industries

  • Biotechnological Institutes

  • Medical Laboratories

  • Market Research And Consulting Service Providers 


Figure 1:- Global performance enhancing drugs market share, by region
Performance Enhancing Drugs Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The global performance enhancing drugs market is segmented on the basis of types, products, and end users.


On the basis of types, the market is segmented into ergogenic aids, nootropic, and others. The ergogenic aids segment by types is sub-segmented into anabolic steroids, dehydroepiandrosterone (DHEA), human growth hormone, and others. The nootropic segment by types is further segmented into racetams, ampakines, choline & acetylcholine intermediates, others.


On the basis of the products, the market is categorised into pills, injections, patches, and others


On the basis of end users, the market is segmented into athletes, body builders, students, militaries, and others. 


Regional Analysis


The Americas dominates the global performance enhancing drugs market owing to the presence of well-developed economies with high per capita income within the region like the U.S. and Canada. In 2017, according to the American Cancer Society in the U.S., about 252,710 new cases of invasive breast cancer diagnosed in women. Moreover, it is predicted that by the end of 2017, 40,610 women would die from breast cancer. This will boost the market growth during the forecasted period as anabolic steroids can be for the treatment of certain types of breast cancer. 


Europe is the second largest performance enhancing drug market, which is followed by Asia Pacific. Availability of funds for research and increasing acceptance of the performance enhancing drugs within the region likely to boost the market.


Asia Pacific is the fastest growing region for the market due to the increasing awareness of the performance enhancing drugs, continuously developing economies, and presence of huge opportunity in the market.


On the other hand, the Middle East & Africa owns the least share of the global performance enhancing drugs market due to presence of poor economy, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology
Performance Enhancing Drugs Market-


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players for global performance enhancing drugs market


The key players in the global performance enhancing drugs market are Taj Pharmaceuticals Limited. (India), Balkan Pharmaceuticals. (Europe), Bayer AG (Europe), AstraZeneca (Europe), Novo Nordisk A/S (Europe), BrainAlert, LLC (U.S.), Douglas Laboratories. (U.S.), Onnit Labs, LLC. (U.S.), Eli Lilly and Company. (U.S.), and others.



Frequently Asked Questions (FAQ) :


Performance enhancing drugs are drugs that elevate the consumer’s athletic performance by providing benefits such as muscle enlargement and increased oxygen carrying capacity.

The Performance Enhancing Drugs Market is expected to exhibit a strong 4.8% CAGR over the forecast period from 2018 to 2023.

Growing acceptance of performance enhancing drugs among amateur bodybuilders and fitness enthusiasts is the major driver for the market.

The Americas dominate the Global Performance Enhancing Drugs Market.

Leading players in the Performance Enhancing Drugs Market include Novo Nordisk, Taj Pharmaceuticals, and Bayer AG, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Performance Enhancing Drugs Market, by Type

6.1 Introduction

6.2 Ergogenic Aids

Market Estimates & Forecast, 2020 – 2027

6.2.1 Anabolic Steroids

6.2.2 Dehydroepiandrosterone (DHEA)

6.2.3 Human Growth Hormone

6.2.4 Others

6.3 Nootropic

Market Estimates & Forecast, 2020 – 2027

6.3.1 Racetams

6.3.2 Ampakines

6.3.3 Choline & Acetylcholine Intermediates

6.3.4 Others

6.4 Others

Chapter 7. Global Performance Enhancing Drugs Market, by Products

7.1 Introduction

7.2 Pills

Market Estimates & Forecast, 2020 – 2027

7.3 Injections

Market Estimates & Forecast, 2020 – 2027

7.4 Patches

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Market Estimates & Forecast, 2020 – 2027

Chapter 8 Global Performance Enhancing Drugs Market, by End User

8.1 Introduction

8.2 Athletes

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Body Builders

8.2.2 Market Estimates & Forecast, 2020 – 2027

8.4 Students

8.2.3 Market Estimates & Forecast, 2020 – 2027

8.5 Militaries

8.2.4 Market Estimates & Forecast, 2020 – 2027

8.6 Others

8.2.5 Market Estimates & Forecast, 2020 – 2027

Chapter 9. Global Performance Enhancing Drugs Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Taj Pharmaceuticals Limited.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Balkan Pharmaceuticals.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bayer AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 AstraZeneca

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Novo Nordisk A/S

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 BrainAlert, LLC

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Douglas Laboratories.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Onnit Labs, LLC.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8 Eli Lilly and Company.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Performance Enhancing Drugs Market

Chapter 13 Appendix

LIST OF TABLES

Table 1 Performance Enhancing Drugs Industry Synopsis, 2020 – 2027

Table 2 Global Performance Enhancing Drugs Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Performance Enhancing Drugs Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 6 Global Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 8 North America Performance Enhancing Drugs by Products, 2020 – 2027, (USD Million)

Table 9 North America Performance Enhancing Drugs by End Users, 2020 – 2027, (USD Million)

Table 10 US Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 11 US Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 12 US Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 14 Canada Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 15 Canada Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 17 South America Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 18 South America Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table19 Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 20 Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 21 Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 23 Western Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 24 Western Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Performance Enhancing Drugs Market

Figure 3 Segmentation Market Dynamics for Global Performance Enhancing Drugs Market

Figure 4 Global Performance Enhancing Drugs Market Share, by Type 2020

Figure 5 Global Performance Enhancing Drugs Market Share, by Products 2020

Figure 6 Global Performance Enhancing Drugs Market Share, by End Users, 2020

Figure 7 Global Performance Enhancing Drugs Market Share, by Region, 2020

Figure 8 North America Performance Enhancing Drugs Market Share, by Country, 2020

Figure 9 Europe Performance Enhancing Drugs Market Share, by Country, 2020

Figure 10 Asia Pacific Performance Enhancing Drugs Market Share, by Country, 2020

Figure 11 Middle East & Africa Rickets Market Share, by Country, 2020

Figure 12 Global Performance Enhancing Drugs Market: Company Share Analysis, 2020 (%)

Figure 13 Taj Pharmaceuticals Limited. : Key Financials

Figure 14 Taj Pharmaceuticals Limited. : Segmental Revenue

Figure 15 Taj Pharmaceuticals Limited. : Geographical Revenue

Figure 16 Balkan Pharmaceuticals. : Key Financials

Figure 17 Balkan Pharmaceuticals. : Segmental Revenue

Figure 18 Balkan Pharmaceuticals. : Geographical Revenue

Figure 19 Bayer AG. : Key Financials

Figure 20 Bayer AG. : Segmental Revenue

Figure 21 Bayer AG. : Geographical Revenue

Figure 22 AstraZeneca: Key Financials

Figure 23 AstraZeneca: Segmental Revenue

Figure 24 AstraZeneca: Geographical Revenue

Figure 25 Novo Nordisk A/S: Key Financials

Figure 26 Novo Nordisk A/S: Segmental Revenue

Figure 27 Novo Nordisk A/S: Geographical Revenue

Figure 28 BrainAlert, LLC: Key Financials

Figure 29 BrainAlert, LLC: Segmental Revenue

Figure 30 BrainAlert, LLC: Geographical Revenue

Figure 31 Douglas Laboratories.: Key Financials

Figure 32 Douglas Laboratories.: Segmental Revenue

Figure 33 Douglas Laboratories.: Geographical Revenue

Figure 34 Onnit Labs, LLC. : Key Financials

Figure 35 Onnit Labs, LLC.: Segmental Revenue

Figure 36 Onnit Labs, LLC. : Geographical Revenue

Figure 37 Eli Lilly and Company. : Key Financials

Figure 38 Eli Lilly and Company. : Segmental Revenue

Figure 39 Eli Lilly and Company. : Geographical Revenue